Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Introgen’s Advexin Doubles Survival In Some Head & Neck Cancer Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm plans end-of-June filing in U.S. and EU for p53 tumor suppressor in recurrent head and neck cancer.

You may also be interested in...



Introgen Files Advexin For Head And Neck Cancer In U.S., EU

Biotech says it hopes to follow the Idec/Rituxan model in bringing oncologic gene therapy to the U.S. market.

Introgen Files Advexin For Head And Neck Cancer In U.S., EU

Biotech says it hopes to follow the Idec/Rituxan model in bringing oncologic gene therapy to the U.S. market.

Introgen Advexin Data Strengthens Biomarker Case In Head And Neck Cancer Patients

BLA filing for the p53 tumor suppressor remains on track for the second quarter, Medical and Scientific Affairs VP Sobol tells “The Pink Sheet” DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel